Bonfrer JM - Search Results

1

Monitoring of impending myocardial damage after pleuropneumonectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma using biochemical markers.

Klaase JM, Swaanenburg JC, Schouwink H, Sosef MN, Bonfrer JM, Zoetmulder FA, Rutgers EJ, Baas P. Klaase JM, et al. Among authors: bonfrer jm. Photochem Photobiol. 2000 Mar;71(3):351-4. doi: 10.1562/0031-8655(2000)071<0351:moimda>2.0.co;2. Photochem Photobiol. 2000. PMID: 10732455

2

Cyfra 21-1 and TPA as markers in malignant mesothelioma.

Bonfrer JM, Schouwink JH, Korse CM, Baas P. Bonfrer JM, et al. Anticancer Res. 1997 Jul-Aug;17(4B):2971-3. Anticancer Res. 1997. PMID: 9329578

3

Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.

Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P. Schouwink H, et al. Among authors: bonfrer jm. Lung Cancer. 1999 Jul;25(1):25-32. doi: 10.1016/s0169-5002(99)00044-6. Lung Cancer. 1999. PMID: 10466859

4

Non-invasive diagnosis of pleural malignancies: the role of tumour markers.

van den Heuvel MM, Korse CM, Bonfrer JM, Baas P. van den Heuvel MM, et al. Among authors: bonfrer jm. Lung Cancer. 2008 Mar;59(3):350-4. doi: 10.1016/j.lungcan.2007.08.030. Epub 2007 Oct 22. Lung Cancer. 2008. PMID: 17933420

5

Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion.

Vrouenraets BC, Kroon BB, Klaase JM, Bonfrer JM, Nieweg OE, van Slooten GW, van Dongen JA. Vrouenraets BC, et al. Among authors: bonfrer jm. Ann Surg Oncol. 1997 Jan;4(1):88-94. doi: 10.1007/BF02316815. Ann Surg Oncol. 1997. PMID: 8985522

6

Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.

van Ruth S, Hart AA, Bonfrer JM, Verwaal VJ, Zoetmulder FA. van Ruth S, et al. Among authors: bonfrer jm. Ann Surg Oncol. 2002 Dec;9(10):961-7. doi: 10.1007/BF02574513. Ann Surg Oncol. 2002. PMID: 12464587

7

An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.

Korse CM, Taal BG, Bonfrer JMG, Vincent A, van Velthuysen ML, Baas P. Korse CM, et al. Among authors: bonfrer jmg. Ann Oncol. 2011 Dec;22(12):2625-2630. doi: 10.1093/annonc/mdr007. Epub 2011 Mar 17. Ann Oncol. 2011. PMID: 21415235 Free article.

8

SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity.

Gast MC, Bonfrer JM, van Dulken EJ, de Kock L, Rutgers EJ, Schellens JH, Beijnen JH. Gast MC, et al. Among authors: bonfrer jm. Cancer Biomark. 2006;2(6):235-48. doi: 10.3233/cbm-2006-2602. Cancer Biomark. 2006. PMID: 17264395 Free article.

9

Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours.

Korse CM, Bonfrer JM, Prevoo W, Baas P, Taal BG. Korse CM, et al. Among authors: bonfrer jm. Tumour Biol. 2011 Aug;32(4):647-52. doi: 10.1007/s13277-011-0164-7. Epub 2011 Mar 5. Tumour Biol. 2011. PMID: 21373992 Free article.

10

Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).

Gast MC, van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, Schellens JH, Beijnen JH. Gast MC, et al. Among authors: bonfrer jm. Clin Chem Lab Med. 2009;47(6):694-705. doi: 10.1515/CCLM.2009.151. Clin Chem Lab Med. 2009. PMID: 19416081

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters